Aurobindo Pharma

Sector: Pharmaceuticals  |  HQ: Hyderabad, Telangana, India  |  Founded: 1986  |  Employees: 27,000+

Listed as: NSE / BSE listed (AUROPHARMA)  |  NSE / BSE  |  Ticker: AUROPHARMA.NS

Company overview

Aurobindo Pharma is one of India's largest pharmaceutical companies by revenue and one of the world's largest generic drug producers, with a particular leadership position in the United States generics market. Founded in 1986 by P V Ramprasad Reddy, K Nityananda Reddy and a small group of co founders, the company is headquartered in Hyderabad and is dual listed on the BSE and NSE. Aurobindo manufactures and markets generic finished dosages, active pharmaceutical ingredients, biosimilars and specialty pharmaceuticals across more than 150 countries. The company's product portfolio spans the full breadth of generic therapeutic categories, including anti retrovirals, cardiovasculars, central nervous system drugs, anti diabetics, anti infectives, gastroenterological drugs and pain management. Aurobindo operates a wide network of manufacturing facilities in Telangana, Andhra Pradesh, Maharashtra and overseas, with multiple sites approved by the US Food and Drug Administration, European Medicines Agency, UK MHRA, Japan PMDA, WHO Geneva and other major regulators. The company is also a significant API producer, with vertical integration in many of its key molecules.

Financial performance and recent trajectory

Disclosed revenue (FY25): ₹31,000+ crore (FY 2024-25).

12-month price trajectory

Monthly closes over the last 12 months. Source: Yahoo Finance.

Competitive position

Aurobindo Pharma is consistently among the top five Indian pharmaceutical companies by revenue alongside Sun Pharma, Dr Reddy's Laboratories, Cipla and Lupin. In the United States generics market, where it derives nearly half of its revenue, it ranks among the top three generic suppliers by prescription volume and number of approved abbreviated new drug applications. Globally it competes with Teva, Sandoz, Viatris, Hikma and other generic majors. Its advantage is vertical integration from API to finished dosage, deep ANDA pipeline depth, and scale at low cost Indian sites. Its disadvantage relative to Sun Pharma or Dr Reddy's is a thinner specialty and complex generics portfolio, although biosimilars and injectables investments are gradually closing that gap.

Key risks

FDA inspection and warning letter exposure at key sites China dependence for selected starting materials Currency volatility and US generics pricing pressure

Outlook

Aurobindo Pharma was founded in 1986 in Hyderabad by P V Ramprasad Reddy and K Nityananda Reddy with a focus on semi synthetic penicillin manufacturing. The company expanded through the 1990s as a bulk drug producer and listed on Indian stock exchanges in 1995. The transformation into a global generic finished dosage producer accelerated in the 2000s, when Aurobindo invested heavily in regulated market formulations, particularly for the United States. The business is organised into two broad reporting segments, formulations and active pharmaceutical ingredients. Formulations contribute the majority of revenue and are further split by geography, with the United States as the single largest market, followed by Europe, growth markets including South Africa, Brazil, Mexico, Saudi Arabia and the Anglophone West African region, and the anti retroviral business serving global procurement agencies including PEPFAR and the Global Fund. The API segment supplies internal formulation requirements and external customers across cephalosporins, semi synthetic penicillins, anti retrovirals, central nervous system drugs and cardiovasculars. Manufacturing capability is anchored across more than two dozen facilities, including formulation units in Hyderabad, Visakhapatnam, Pithampur and Naidupeta, API plants in Bhongir, Pydibhimavaram, Jeedimetla and other Telangana and Andhra Pradesh clusters, and overseas units in the United States and Portugal. The company has consistently invested in inspection readiness and has received multiple Form 483 and warning letter remediation cycles, a pattern common across the large Indian generic producers. Distribution in the United States is through the consolidated wholesaler channel served by McKesson, Cencora and Cardinal Health, with hospital and institutional channels served separately. In Europe and growth markets Aurobindo sells through its own subsidiaries and through tender driven institutional channels. The company has built strong tender execution capability in the European Union and in emerging market procurement, where reliability of supply at competitive prices is decisive. Financials for FY 2024-25 show revenue above ₹31,000 crore with EBITDA margins in the high teens, reflecting the partial recovery from the historically weak US generics pricing environment of 2018-2022. The company has continued to invest in research and development at around five to six per cent of revenue, with focus on injectables, biosimilars, peptides, vaccines and selected specialty assets. Recent strategic moves include the build out of the biosimilars business under the CuraTeQ Biologics platform, which has secured first commercial launches in regulated markets and is investing in a state of the art biologics facility in Hyderabad. The company has also expanded its injectables footprint through Eugia Pharma, a subsidiary focused on complex injectables and oral solids for differentiated generic categories. Aurobindo entered the vaccines space through Auro Vaccines and is developing a portfolio that includes recombinant vaccines for global procurement. Strategy from 2025 to 2030 is built on three pillars. First, sustaining the generics base business through scale, vertical integration and continued ANDA filings. Second, scaling the biosimilars portfolio under CuraTeQ, with eight to ten products targeted for regulated market launches over the next five years. Third, deepening the injectables and specialty generics franchise to move up the value chain. The regulatory environment is intense. The company is subject to the US FDA, EMA, UK MHRA, Japan PMDA, Health Canada, TGA Australia, ANVISA Brazil, WHO Geneva and a long list of country regulators, each with its own inspection regime. In India it complies with the Drugs and Cosmetics Act 1940 and the Central Drugs Standard Control Organisation, the Pharmacy Act, environmental regulations under the Water and Air Acts, and the standards of the Indian Pharmacopoeia. As a listed company it complies with Companies Act 2013 and SEBI LODR. Risks include US generic price erosion, FDA inspection outcomes at key sites, currency volatility on dollar denominated revenue, raw material concentration from China for certain key starting materials, regulatory enforcement around environmental compliance at API plants, and litigation exposure including price fixing investigations that have affected the broader US generics industry. The transition into biosimilars and complex injectables introduces execution and capital intensity risk. Management is led by P V Ramprasad Reddy and K Nityananda Reddy as co founders, with K Ragunathan as chairman, Penaka Sarath Chandra Reddy as managing director and a senior leadership team across formulations, API, R&D and global commercial. Governance has been strengthened with independent directors covering audit, nomination and remuneration, and risk committees. ESG disclosures include water positive operations at several sites, renewable energy share growth, effluent zero discharge targets at API plants, and community health initiatives in the operating regions. The company reports under the Business Responsibility and Sustainability Report framework mandated by SEBI for the top listed companies.

KAMRIT point of view

Building or competing with Aurobindo?

KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the pharmaceuticals sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of Aurobindo and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.

View all 1 related project report → Book a scoping call

Related KAMRIT project reports

These reports use Aurobindo Pharma in benchmarking and competitive analysis sections.

Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.